Neuspera Medical announced today that it appointed Bunty Banerjee as its first chief operating officer (COO).

The San Jose, California-based sacral neuromodulation (SNM) technology developer said Banerjee will lead activities in R&D and operations while working closely with all other functions. His appointment comes as the company completes a new FDA submission for its neuromodulation system. The company also has commercialization preparations underway for the system, which aims to treat overactive bladder (OAB).

Neuspera — which featured on our list of 7 neurotech companies you need to know — also recently raised $23 million in a Series D round.

“Bunty is joining Neuspera at an incredibly exciting time for the company,” said Steffen Hovard, CEO of Neuspera Medical. “We look forward to his contributions to the team as he deploys valuable skills and insights with the organization.”

Neuspera’s discreet, non-invasive device received FDA clearance last year for the treatment of chronic pain of peripheral nerve origin. It’s currently an investigational device for treating urinary urge incontinence (UUI), a symptom associated with OAB.

Banerjee, a seasoned life sciences executive, has more than 25 years of experience in the medical device industry. He held senior operational leadership positions at Omnicell, Philips, Abbott and Boston Scientific before joining Neuspera.

“I am absolutely thrilled to join the Neuspera team and contribute to the company’s success at this critical stage,” said Banerjee. “I’m looking forward to being a part of an incredibly innovative team and an amazing technology dedicated to improving the lives of patients with chronic health conditions.”